• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

液-抗溶剂沉淀法(LASP)制备西洛他唑纳米混悬剂的系统方法及其与超声结合的研究。

A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.

机构信息

Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 6 Grunwaldzka Street, 60-780 Poznan, Poland.

出版信息

Int J Mol Sci. 2021 Nov 17;22(22):12406. doi: 10.3390/ijms222212406.

DOI:10.3390/ijms222212406
PMID:34830298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8619020/
Abstract

Nanosizing is an approach to improve the dissolution rate of poorly soluble drugs. The first aim of this work was to develop nanosuspension of cilostazol with liquid antisolvent precipitation (LASP) and its combination with ultrasound. Second, to systematically study the effect of bottom-up processing factors on precipitated particles' size and identify the optimal settings for the best reduction. After solvent and stabilizer screening, in-depth process characterization and optimization was performed using Design of Experiments. The work discusses the influence of critical factors found with statistical analysis: feed concentration, stabilizer amount, stirring speed and ultrasound energy governed by time and amplitude. LASP alone only generated particle size of a few microns, but combination with ultrasound was successful in nanosizing (d10 = 0.06, d50 = 0.33, d90 = 1.45 µm). Micro- and nanosuspension's stability, particle morphology and solid state were studied. Nanosuspension displayed higher apparent solubility than equilibrium and superior dissolution rate over coarse cilostazol and microsuspension. A bottom-up method of precipitation-sonication was demonstrated to be a successful approach to improve the dissolution characteristics of poorly soluble, BCS class II drug cilostazol by reducing its particle size below micron scale, while retaining nanosuspension stability and unchanged crystalline form.

摘要

纳米化是一种提高难溶性药物溶解速率的方法。本工作的首要目标是开发西洛他唑的纳米混悬液,采用液相反溶剂沉淀(LASP)法及其与超声的联合应用。其次,系统研究底向上加工因素对沉淀颗粒粒径的影响,确定最佳条件以实现最佳减小效果。在筛选出溶剂和稳定剂后,使用实验设计进行深入的工艺特性研究和优化。本文讨论了通过统计分析发现的关键因素的影响:进料浓度、稳定剂用量、搅拌速度和超声能量(由时间和幅度控制)。单独使用 LASP 只能得到几微米的粒径,但与超声联合使用成功地实现了纳米化(d10 = 0.06,d50 = 0.33,d90 = 1.45 µm)。研究了微纳米混悬液的稳定性、颗粒形态和固体状态。纳米混悬液的表观溶解度高于平衡溶解度,且比粗西洛他唑和微混悬液具有更高的溶解速率。沉淀-超声的底向上方法被证明是一种成功的方法,可以通过将难溶性 BCS 类 II 药物西洛他唑的粒径减小到亚微米以下,同时保持纳米混悬液的稳定性和不变的晶体形态,来改善其溶解特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/e383f8415e54/ijms-22-12406-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/45c21374349a/ijms-22-12406-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/ea27b651d560/ijms-22-12406-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/6362d87e3cff/ijms-22-12406-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/0007fa4dabaf/ijms-22-12406-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/002636917d98/ijms-22-12406-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/62353d0f9c8f/ijms-22-12406-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/22e9e3038547/ijms-22-12406-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/ccc49f0891f4/ijms-22-12406-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/542935659abf/ijms-22-12406-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/7e96bfcbd30d/ijms-22-12406-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/365b30ee6dd2/ijms-22-12406-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/93fff56daf87/ijms-22-12406-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/a1fa89b0870f/ijms-22-12406-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/62851be796da/ijms-22-12406-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/8d04c3af3dcb/ijms-22-12406-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/24a4e4d71a76/ijms-22-12406-g010a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/cb0130b2e0f9/ijms-22-12406-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/800e7572828e/ijms-22-12406-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/bb706579cabc/ijms-22-12406-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/7bd20658fe20/ijms-22-12406-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/c1157b24b885/ijms-22-12406-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/f959b753b659/ijms-22-12406-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/e383f8415e54/ijms-22-12406-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/45c21374349a/ijms-22-12406-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/ea27b651d560/ijms-22-12406-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/6362d87e3cff/ijms-22-12406-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/0007fa4dabaf/ijms-22-12406-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/002636917d98/ijms-22-12406-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/62353d0f9c8f/ijms-22-12406-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/22e9e3038547/ijms-22-12406-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/ccc49f0891f4/ijms-22-12406-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/542935659abf/ijms-22-12406-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/7e96bfcbd30d/ijms-22-12406-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/365b30ee6dd2/ijms-22-12406-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/93fff56daf87/ijms-22-12406-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/a1fa89b0870f/ijms-22-12406-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/62851be796da/ijms-22-12406-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/8d04c3af3dcb/ijms-22-12406-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/24a4e4d71a76/ijms-22-12406-g010a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/cb0130b2e0f9/ijms-22-12406-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/800e7572828e/ijms-22-12406-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/bb706579cabc/ijms-22-12406-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/7bd20658fe20/ijms-22-12406-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/c1157b24b885/ijms-22-12406-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/f959b753b659/ijms-22-12406-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4383/8619020/e383f8415e54/ijms-22-12406-g017.jpg

相似文献

1
A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.液-抗溶剂沉淀法(LASP)制备西洛他唑纳米混悬剂的系统方法及其与超声结合的研究。
Int J Mol Sci. 2021 Nov 17;22(22):12406. doi: 10.3390/ijms222212406.
2
Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.通过液体反溶剂沉淀技术提高花旗松素纳米颗粒的溶解度、抗氧化能力和生物利用度。
Int J Pharm. 2014 Aug 25;471(1-2):366-76. doi: 10.1016/j.ijpharm.2014.05.049. Epub 2014 Jun 2.
3
Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.通过质量源于设计(QbD)方法制备并表征用于提高呋塞米溶出速率的稳定纳米混悬液
Curr Drug Deliv. 2018;15(5):672-685. doi: 10.2174/1567201815666180123094320.
4
Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.研究纳米晶型以提高难溶性西洛他唑的口服生物利用度。
J Pharm Pharm Sci. 2011;14(2):196-214. doi: 10.18433/j3pw2w.
5
Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.超声辅助沉淀法制备氯雷他定纳米混悬剂的设计与表征。
Eur J Pharm Sci. 2018 Sep 15;122:94-104. doi: 10.1016/j.ejps.2018.06.010. Epub 2018 Jun 14.
6
Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.通过超声沉淀法制备无定形纳米混悬剂并利用实验设计方法进行制剂和工艺优化。
Int J Pharm. 2019 Mar 25;559:348-359. doi: 10.1016/j.ijpharm.2019.01.054. Epub 2019 Feb 2.
7
Continuous production of aqueous suspensions of ultra-fine particles of curcumin using ultrasonically driven mixing device.超声驱动混合装置连续制备姜黄素超细微粒水悬浮液。
Pharm Dev Technol. 2018 Jul;23(6):608-619. doi: 10.1080/10837450.2017.1315133. Epub 2017 Apr 24.
8
Amorphous isradipine nanosuspension by the sonoprecipitation method.采用超声沉淀法制备无定型异乐定纳米混悬剂。
Int J Pharm. 2014 Oct 20;474(1-2):146-50. doi: 10.1016/j.ijpharm.2014.08.017. Epub 2014 Aug 17.
9
Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives.采用超临界抗溶剂法提高西洛他唑的润湿性和溶解性能:各种添加剂的影响
Chem Pharm Bull (Tokyo). 2010 Feb;58(2):230-3. doi: 10.1248/cpb.58.230.
10
Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.拉西地平纳米混悬液的溶解度和溶出速率增强:通过反溶剂声沉淀技术制备及采用Box-Behnken设计进行优化
AAPS PharmSciTech. 2017 May;18(4):983-996. doi: 10.1208/s12249-016-0604-1. Epub 2016 Aug 9.

引用本文的文献

1
Nanosizing and Surface Modification by Propellant Assisted Aerosolization Enhances Solubility and Dissolution of Estradiol.通过推进剂辅助雾化进行纳米尺寸控制和表面改性可提高雌二醇的溶解度和溶出度。
AAPS PharmSciTech. 2025 Jun 6;26(5):165. doi: 10.1208/s12249-025-03151-2.
2
Development of a Carvedilol-Loaded Solid Self-Nanoemulsifying System with Increased Solubility and Bioavailability Using Mesoporous Silica Nanoparticles.使用介孔二氧化硅纳米颗粒开发具有更高溶解度和生物利用度的载卡维地洛固体自纳米乳化系统。
Int J Mol Sci. 2025 Feb 13;26(4):1592. doi: 10.3390/ijms26041592.
3
Drug nanocrystals: Surface engineering and its applications in targeted delivery.

本文引用的文献

1
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.西洛他唑:基础机制与临床应用综述。
Cardiovasc Drugs Ther. 2022 Aug;36(4):777-792. doi: 10.1007/s10557-021-07187-x. Epub 2021 Apr 16.
2
Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.西洛他唑在 COVID-19 治疗中可能有益吗?考虑将磷酸二酯酶-3 作为治疗靶点。
Int Immunopharmacol. 2021 Mar;92:107336. doi: 10.1016/j.intimp.2020.107336. Epub 2020 Dec 28.
3
Can the cavi-precipitation process be exploited to generate smaller size drug nanocrystal?
药物纳米晶体:表面工程及其在靶向递送中的应用。
iScience. 2024 Oct 16;27(11):111185. doi: 10.1016/j.isci.2024.111185. eCollection 2024 Nov 15.
4
Targeted Delivery to Dying Cells Through P-Selectin-PSGL-1 Axis: A Promising Strategy for Enhanced Drug Efficacy in Liver Injury Models.通过 P-选择素-PSGL-1 轴靶向递送至濒死细胞:一种增强肝损伤模型中药物疗效的有前途的策略。
Cells. 2024 Oct 27;13(21):1778. doi: 10.3390/cells13211778.
能否利用共沉淀法生成更小粒径的药物纳米晶?
Drug Dev Ind Pharm. 2021 Feb;47(2):235-245. doi: 10.1080/03639045.2020.1871004. Epub 2021 Jan 22.
4
Fabrication of Ibrutinib Nanosuspension by Quality by Design  Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.通过质量源于设计方法制备伊布替尼纳米混悬剂:旨在提高口服生物利用度和降低快速进食变异性。
AAPS PharmSciTech. 2019 Oct 28;20(8):326. doi: 10.1208/s12249-019-1524-7.
5
Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.通过超声沉淀法制备无定形纳米混悬剂并利用实验设计方法进行制剂和工艺优化。
Int J Pharm. 2019 Mar 25;559:348-359. doi: 10.1016/j.ijpharm.2019.01.054. Epub 2019 Feb 2.
6
Enhanced dissolution and oral bioavailbility of cinacalcet hydrochlorde nanocrystals with no food effect.盐酸西那卡塞纳米晶提高药物溶出度和口服生物利用度且无食物影响。
Nanotechnology. 2019 Feb 1;30(5):055102. doi: 10.1088/1361-6528/aaef46. Epub 2018 Dec 4.
7
Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.超声辅助沉淀法制备氯雷他定纳米混悬剂的设计与表征。
Eur J Pharm Sci. 2018 Sep 15;122:94-104. doi: 10.1016/j.ejps.2018.06.010. Epub 2018 Jun 14.
8
Enhanced percutaneous absorption of cilostazol nanocrystals using aqueous gel patch systems and clarification of the absorption mechanism.使用水凝胶贴剂系统增强西洛他唑纳米晶体的经皮吸收并阐明吸收机制。
Exp Ther Med. 2018 Apr;15(4):3501-3508. doi: 10.3892/etm.2018.5820. Epub 2018 Jan 31.
9
An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats.西洛他唑纳米颗粒的口服制剂可增强大鼠肠道对药物的吸收。
Exp Ther Med. 2018 Jan;15(1):454-460. doi: 10.3892/etm.2017.5373. Epub 2017 Oct 24.
10
Drug nanocrystals - Versatile option for formulation of poorly soluble materials.药物纳米晶体 - 用于制备难溶性物质的多功能选择。
Int J Pharm. 2018 Feb 15;537(1-2):73-83. doi: 10.1016/j.ijpharm.2017.12.005. Epub 2017 Dec 17.